DelveInsight’s “Fuchs Endothelial Corneal Dystrophy (FECD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fuchs Endothelial Corneal Dystrophy Market trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Highlights from the Fuchs Endothelial Corneal Dystrophy (FECD) Market Report
Learn more about the key trends and developments driving the market growth @ Fuchs Endothelial Corneal Dystrophy Market Landscape
Fuchs Endothelial Corneal Dystrophy (FECD) Overview
Fuchs Endothelial Corneal Dystrophy is the defect in the eye’s cornea where endothelial cells degenerate or get damaged. These are sporadic or inherited in an auto-dominant manner. It is characterized by the swelling of the cornea, progressive loss of corneal endothelial cells, thickening of the Descemet’s membrane, and deposition of extracellular matrix in the form of guttae. Swelling of the cornea leads to glare, halo, and reduced visual acuity, eventually leading to corneal blindness.
Descemet’s Stripping Only (DSO) – DWEK is the latest surgical option for some patients with Fuchs, in which the ophthalmologist carefully strips away a 4 mm circle of central diseased endothelial cells without placing any donor cornea tissue. If the surgery succeeds, healthy endothelial cells from the intact periphery will migrate centrally, covering the defect and providing good quality vision.
Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology Segmentation
The Fuchs Endothelial Corneal Dystrophy proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Download the Fuchs Endothelial Corneal Dystrophy market report to understand which factors are influencing epidemiology trends @ Fuchs Endothelial Corneal Dystrophy Epidemiological Insights
Fuchs Endothelial Corneal Dystrophy (FECD) Market
There are no FDA-approved pharmacological therapies available for FECD. If one has a severe form of the disease, minimally invasive lamellar endothelial keratoplasty (EK) procedures can be used.
Currently, various new therapies are being developed to address the unmet need and to provide certain therapy in the initial stages of the disease. Some of the most prominent ones include Ripasudil (K-321), TTHX1114, EO2002, and STN1010904/AE-001. The launch of emerging therapies is expected to transform the treatment scenario in the coming years.
To learn more about the development in the Fuchs Endothelial Corneal Dystrophy therapeutics market @ Fuchs Endothelial Corneal Dystrophy Market Analysis
Fuchs Endothelial Corneal Dystrophy (FECD) Market Drivers
Fuchs Endothelial Corneal Dystrophy (FECD) Therapeutics Assessment
The FECD pipeline is robust with various drugs at different stages of development expected to launch in the coming years. Some of the key therapies under development include.
And many others
Discover more about therapies set to grab major market share @ Fuch’s Endothelial Dystrophy Market therapeutics outlook
Scope of the Fuch’s Endothelial Dystrophy (FECD) Market Report:
Get in touch with our Business executive @ Fuchs Endothelial Corneal Dystrophy Market Landscape Analysis
Table of Contents
1.
Fuchs Endothelial Corneal Dystrophy (FECD) Market Key Insights
2.
Fuchs Endothelial Corneal Dystrophy (FECD) Market Report Introduction
3.
Fuchs Endothelial Corneal Dystrophy (FECD) Market Overview at a Glance
4.
Fuchs Endothelial Corneal Dystrophy (FECD) Market Executive Summary
5.
Disease Background and Overview
6.
Fuchs Endothelial Corneal Dystrophy (FECD) Treatment and Management
7.
Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology and Patient Population
8.
Patient Journey
10.
Fuchs Endothelial Corneal Dystrophy (FECD) Emerging Drugs
12.
Fuchs Endothelial Corneal Dystrophy (FECD) Market Outlook
13.
Potential of Current and Emerging Therapies
14.
KOL Views
15.
16.
Fuchs Endothelial Corneal Dystrophy (FECD) Market Barriers
17.
Unmet Needs
18.
SWOT Analysis
19.
Appendix
20.
DelveInsight Capabilities
21.
Disclaimer
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/